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Abstract
Introduction: Inherited alpha-1 antitrypsin (AAT) deficiency is one of the three most common genetic disorders in Cauca-
sians. It considerably increases the risk of progressive obstructive lung diseases, mostly chronic obstructive pulmonary 
disease. It has also been suggested that AAT deficiency might be instrumental vasculitis associated with the anti-neutrophil 
cytoplasm antibodies (cANCA) and subsequent lung tissue injury. 
Material and methods: We present the results from a pilot study involving 51 patients with granulomatosis with polyangiitis, 
formerly known as Wegener’s granulomatosis (GPA), 43 of whom were cANCA positive. The control group consisted of 658 
individuals. AAT blood concentration assessment by nephelometry, phenotyping by isoelectrofocusing and real-time PCR 
genotyping were performed. 
Results: Deficiency alleles PI*Z and PI*S were detected in 3 (5.88%) and in 2 patients (3.92%) with GPA, respectively. All 
of them were cANCA positive. In the controls, PI*Z was observed in 2.8% while PI*S in 1.5% of cases. Accordingly, the 
increased incidence of main deficiency alleles was demonstrated in GPA, and particularly in cANCA+GPA patients, when 
compared to the controls. The estimated frequency for PI*Z in GPA, cANCA+GPA patients and controls was, respectively, 
29.4/1000, 34.9/1000 and 13.7/1000, whereas for PI*S it was 19.2/1000, 23.2/10,00 and 7.6/1000. However, the observed 
differences did not reach statistical significance due to the considerable size disproportion between groups. 
Consclusions: We believe that our preliminary data confirm the clinical importance of AAT deficiency in GPA patients and 
the need to screen for AAT deficiency alleles. The study is on-going. 
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Streszczenie
Wstęp: Wrodzony niedobór alfa-1 antytrypsyny jest jedną z trzech najczęstszych chorób genetycznych rasy kaukaskiej i wiąże się 
z istotnie wyższym ryzykiem rozwoju postępujących obturacyjnych chorób płuc, zwłaszcza przewlekłej obturacyjnej choroby 
płuc. Niedostateczna aktywność hamująca alfa-1 antytrypsyny wobec proteinaz, a szczególnie proteinazy 3, skutkująca ich 
nadmierną aktywnością przypuszczalnie odgrywa również znaczącą rolę w patomechanizmie ziarniniakowatości z zapaleniem 
naczyń, dawnej ziarniniakowatości Wegenera, zwłaszcza postaci z przeciwciałami skierowanymi przeciwko proteinazie 3 
(cANCA). cANCA-dodatnie zapalenie naczyń jest uznanym wskazaniem do diagnostyki w kierunku wrodzonego niedoboru 
alfa-1 antytrypsyny. 
Materiał i metody: Pilotowym badaniem objęto grupę 51 chorych z potwierdzoną ziarniniakowatością z zapaleniem naczyń 
(GPA) i zajęciem układu oddechowego, u 43 z nich stwierdzono przeciwciała cANCA (cANCA+GPA). Grupę kontrolną stano-
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wiło 658 noworodków przebadanych w ramach populacyjnego badania przesiewowego realizowanego na Mazowszu. 
W próbkach krwi obwodowej wykonano pomiar stężenia alfa-1antytrypsyny metodą nefelometryczną, fenotypowanie 
metodą ogniskowania izoelektycznego oraz genotypowanie metodą real-time PCR. 
Wyniki: Allel deficytowy PI*Z stwierdzono u 3 (5,88%), a PI*S u 2 chorych (3,92%) z GPA, u wszystkich choroba 
przebiegała z obecnością przeciwciał cANCA. W grupie kontrolnej było to odpowiednio u 2,8% oraz 1,5% badanych. 
Zaobserwowano zwiększoną częstość występowania głównych alleli deficytowych u chorych na GPA, 29,4/1000 dla 
PI*Z, w tym 34,9/1000 w podgrupie cANCA+GPA w porównaniu z kontrolą 13,7/1000, natomiast dla PI*S odpowied-
nio 19,2/1000, 23,2/1000 dla cANCA+GPA oraz 7,6/1000 w grupie kontrolnej. Obserwowane różnice nie były istotne 
statystycznie w odniesieniu do kontroli, prawdopodobnie ze względu na różnice w liczebności porównywnych grup. 
Wnioski: Wstępne wyniki badania potwierdzają klinicznie istotną rolę niedoboru AAT oraz potrzebę prowadzenia dia-
gnostyki w tym kierunku u chorych na GPA. Badanie jest kontynuowane.
Słowa kluczowe: wrodzony niedobór alfa-1 antytrypsyny, allel S, allel Z, ziarniniakowatość z zapaleniem naczyń, ANCA
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Introduction
Alpha-1 antitrypsin (AAT) deficiency, one of 
the most common inherited disorders in Cauca-
sian population, is a proven risk factor of lung 
diseases, mainly early-onset emphysema, COPD 
and bronchiectasis. The quantitative deficit of 
alpha-1 antitrypsin, encoded mainly by the PI*S 
and PI*Z deficiency alleles, results in impaired 
proteinase-antiproteinase balance in deficient 
individuals and promotes progressive lung da-
mage [1]. AAT is the main protein inactivating 
neutrophil elastase as the preferred target. Still, 
it is also a cognate inhibitor of other neutrophil-
-derived proteases, such as proteinase 3 (PR3) 
and cathepsin G [2]. PR3 is known to play an 
important role in the mechanisms driving anti- 
-neutrophil cytoplasm antibodies (cANCA) associated 
with vasculitis and ensuing lung tissue injury [3]. 
Hence, it has been suggested that impaired PR3 
inhibition, due to inadequate AAT antiproteinase 
activity and subsequent PR3 hyperactivity, might 
assist in anti-PR3 autoantibody development 
and therefore the pathomechanism of vasculitis. 
Recently, Mota et al. demonstrated significantly 
diminished trypsin inhibitory capacity as well 
as specific AAT activity in the sera of 27 patients 
with GPA; meanwhile, PI*S or PI*Z allele was 
detected in only 5 of them [4]. This link has been 
further strengthened by the current guidelines of 
the ATS/ERS as well as of the Polish Respiratory 
Society enlisting cANCA-associated vasculitis as 
the recommendation for AATD screening, next 
to emphysema and COPD [5, 6]. Here, we pre-
sent the preliminary results from the on-going 
screening program aimed at analysing the frequ-
ency of AAT main deficiency alleles in patients 
with granulomatosis with polyangiitis, formerly 
known as Wegener’s granulomatosis.
Material and methods
Study group
The study group consisted of 51 patients, 28 
female (55%) and 23 male (45%), mean age 46.2 
(17-83) years with diagnosis of granulomatosis with 
polyangiitis in different stages of disease (active, on 
therapy or in remission) based on the clinical symp-
toms supported by either positive ANCA assay or 
a diagnostic biopsy and histopathological evaluation. 
ANCA were evaluated by ELISA and immunofluore-
scence methods. Forty-three subjects proved cANCA 
positive and pANCA negative (84.2%), 2 were cANCA 
negative and pANCA positive (3.9%), and 4 were cAN-
CA and pANCA negative (9.5%). The ANCA status 
of 2 subjects was unknown. The study protocol was 
approved by the local bioethical committee.
The comparative data for the S and Z allele 
prevalence in the general Polish population came 
from the preliminary results of the on-going new-
born screening study in Central Poland (Mazovia 
region). PI*Z and PI*S were assessed in the group of 
658 consecutive neonates born alive at the Duchess 
Anna Mazowiecka University Hospital in Warsaw 
between September 1st and December 31st, 2011 [7].
Materials
Serum and dry blood spot (DBS) samples on 
filter paper were collected simultaneously from all 
GPA patients. Similarly, DBS sampling was per-
formed in newborns, as previously described [7].
Quantitative determination of serum AAT 
concentration by immune nephelometry
The AAT measurement was performed in se-
rum using a rate immune nephelometric method 
(Immage 800 Immunochemistry System, Beckman-
Coulter, USA) with commercially available re-
agents containing goat anti-human AAT antibody 
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(Beckman-Coulter, USA). The normal range for 
AAT in serum samples was 88–174 mg/dL.
AAT phenotyping by isoelectrofocusing (IEF)
Phenotype analysis of serum AAT was per-
formed by IEF on polyacrylamide gel with a pH of 
4.2–4.9 using a Multiphor II Electrophoresis System 
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden), 
as described previously [8]. The AAT phenotype was 
determined by visual inspection and comparison to 
control M1M2, MS, MZ and ZZ samples.
PI*S and PI*Z AAT allele genotyping by real-ti-
me PCR
Genomic DNA was extracted using a commer-
cially available kit: Extract-N-Amp Blood PCR Kits 
(Sigma-Aldrich). Genetic material present in the 
DBS eluate was directly used for AAT genotyping 
without the need for DNA purification from blood, 
as previously described [9]. The identification of 
the two most common mutations of the AAT gene 
(Z, S) was performed in a single reaction by real-ti-
me PCR method using hydrolysing probes coupled 
with fluorescent dyes (VIC or FAM) complementary 
to the mutant variants (PI*S or PI*Z). Primer and 
probe sequences as well as PCR reaction conditions 
were previously described by Struniawski et al. [9].
Prevalence of deficiency alleles Z and S and of 
AAT genotypes was calculated by Hardy-Weinberg 
equation.
Results
Mutated PI*Z or PI*S deficiency alleles were 
detected in 4 subjects out of 51 with GPA (7.84%), 
including PI*Z in 3 (5.88%) and PI*S allele in 2 pa-
tients (3.92%). All of them were cANCA positive; con-
sequently, in the subgroup of cANCA+ GPA patients 
PI*Z and PI*S subjects constituted, respectively, 
6.98% and 4.65%. For comparison, in the controls, 
PI*Z was observed in 2.8% and PI*S in 1.5% of cases. 
Phenotype distribution was as follows: MM in 
47 subjects (92.16%), MZ 2 subjects (3.92 %), MS 
in 1 subject (1.96 %) and SZ in 1 subject (1.96%). 
Mean AAT serum concentration in the total GPA 
group was 201.8 mg/mL (66.1; 178-224; SD; 95% 
confidence interval), while in the cANCA+ GPA 
group it was 186.3 mg/mL (67.2; 166–207), both 
within normal limits. Still, mean AAT serum level 
was 119.43 mg/mL (SD = 48.3) in MZ heterozygo-
tes, 124 mg/mL in MS heterozygote and 58.8 mg/ 
/mL in SZ patient. 
The estimated frequency of PI*Z and PI*S allele 
deficiency in the total GPA group was respectively, 
29.4/1000 and 19.2/1000, while in the controls it 
was 13.7/100 and 7.6/1000, as recently reported for 
the Polish population (Tab. 1). Still, a certain trend 
towards higher incidence of AAT deficiency alleles 
in GPA subjects might be observed. The PI*Z and 
PI*S incidence in cANCA+ group was even higher 
at 34.9/1000 and 23.2/1000, respectively. As before, 
the difference was not statistically significant.
The AAT genotypes distribution in total GPA 
group, cANCA+ GPA subgroup and general popu-
lation are demonstrated in Table 1. 
Discussion
Antineutrophil cytoplasmic antibody (ANCA), 
associated granulomatosis with polyangiitis, is 
characterized by predominant lung involvement 
as well as by autoantibodies against neutrophil de-
rived enzymes. In GPA, ANCA are predominantly 
directed against proteinase 3 (cANCA). Accordin-
gly, in our material cANCA were present in 84.2% 
(n = 43) of patients, while autoantibodies against 
neutrophil myeloperoxidase (p-ANCA) were detec-
ted in 3.9% only (n = 2). 
The high incidence of AAT deficiency alleles 
demonstrated by our pilot study in the examined GPA 
group, and particularly in cANCA+ patients, seems 
to be meaningful, although the observed differences 
Table 1. Estimated frequency for main AAT deficiency alleles and genotypes
Estimated frequency  
of deficiency alleles 
Estimated genotype frequency (1/Hardy-Weinberg)
 PI*Z (95% CI) PI*S (95% CI) Non-S Non-Z Non-SZ ZZ S Non-S SS SZ
GPA
n = 51
29,4  
(–3,3–62,2)
19,2  
(–7,2–46,5)
1/1,10 1/18 1/1156 1/27 1/2601 1/867
cANCA+ GPA
n = 43
34,9  
(–3,9–73,6)
23,2  
(–8,6–55,1)
1/1,12 1/15 1/821 1/22 1/1849 1/616
Controls
n = 658
13,7  
(5,8–21,5)
7,6  
(1,7–13,5)
1/1,04 1/37 1/5345 1/67 1/17319 1/4810
CI —  confidence interval; GPA — Wegener’s granulomatosis; cANCA+ GPA — cANCA positive Wegener’s granulomatosis
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did not reach statistical significance. We believe this 
is attributable to the considerable size differences 
between all compared groups and subgroups.
Importantly, our preliminary results are in 
agreement with several, though not all, previo-
usly published reports. A genetic predisposition 
to GPA has been suggested in the early 90s due to 
several case reports suggesting familial clustering 
[10]. However, Abdou et al. presented discordant 
evidence, finding no familial case within 701 GPA 
patients group, including 12 pairs of twins [11].
The strongest evidence of genetic susceptibi-
lity to GPA came from the gene association studies 
aimed at identifying the candidate genes. In parti-
cular, those encoding the major histocompatibility 
complex (MHC) demonstrating a convincing link to 
ANCA vasculitides. Specifically, HLA-B8, -B50 or 
DR-1, DR-9 and DR2 haplotypes were pointed out by 
most, but not all, studies [12]. Recently, Lyons et al., 
in a cohorts of 1233 UK (discovery cohort) and 1454 
Northern European patients (replication cohort) with 
ANCA-associated vasculitis, confirmed the signifi-
cance of MHC in the genome-wide association study 
[13]. Out of four SNPs (single nucleotide polymor-
phisms) that exceeded the threshold of significance, 
three were located in the MHC region, with gene en-
coding HLA-DPB1 demonstrating the strongest link. 
Interestingly, the fourth was located within SERPINA 
1 gene encoding alpha-1 antitrypsin. 
The association between AATD (mainly PI*Z 
allele) and GPA has been previously indicated. In 
1993 Esnault et al. postulated an association be-
tween the AAT deficiency phenotypes [14]. Soon 
afterwards Elzouki et al. implied the significantly 
increased frequency of PI*Z allele in GPA patients 
of Scandinavian origin, identifying it in as many 
as 17% of their cANCA+ GPA group [15]. In 2001 
Borgmann et al. analysed a population of 79 GPA 
German patients, confirming PI*Z in 7 of them 
(8.86%) and thus the higher prevalence of AAT 
deficient alleles in ANCA vasculitis [16]. Mahr 
et al. studied Z and S allele distribution in 443 
Caucasians with GPA, detecting PI*Z in 7.4% and 
PI*S in 11.4% [17]. Quite a similar relationship is 
implied by our data with PI*Z present in 5.88% of 
the total GPA group and 6.98% of cANCA positive 
patients. Accordingly, the incidence of PI*Z and 
PI*S alleles in our GPA and cANCA+ GPA groups 
is higher than in the Polish population, but not 
significantly. While our pilot study is on-going 
with the intention of extending the GPA group, the 
need for more insightful clinical analyses of Z or 
S carriers with GPA in particular cANCA+ should 
be emphasized. The direct causative link between 
cANCA vasculitis and AAT deficiency alleles S 
and Z has not been proven beyond doubt although 
a considerable number of observations and indirect 
data seem to suggest its existence.
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